Osteosarcoma: Basic science and clinical implications

Orthopedic Clinics of North America

Volumn 37, Issue 1, 2006, Pages 1-7

  Hayden, James B ^a   Hoang, Bang H ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RELAPSE; CANCER RESEARCH; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; LUNG METASTASIS; MEDICAL LITERATURE; MEDICAL RESEARCH; METASTASIS; NECROSIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

AGE FACTORS; AGED; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MOLECULAR BIOLOGY; NEOPLASM STAGING; OSTEOSARCOMA; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 28344447734     PISSN: 00305898     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ocl.2005.06.004     Document Type: Review

References (35)

1. S.S. Bielack, B. Kempf-Bielack, and G. Delling Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols J Clin Oncol 20 2002 776 790
2. P. Picci, S. Ferrari, and G. Bacci Treatment recommendations for osteosarcoma and adult soft tissue sarcomas Drugs 47 1994 82 92
3. E.I. Hauben, S. Weeden, and J. Pringle Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup Eur J Cancer 38 2002 1218 1225
4. B. Kempf-Bielack, S.S. Bielack, and H. Jurgens Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS) J Clin Oncol 23 2005 559 568
5. P.A. Meyers High-dose therapy with autologous stem cell rescue for pediatric sarcomas Curr Opin Oncol 16 2004 120 125
6. J.A. Ross, and S.M. Davies Childhood cancer etiology: recent reports Med Pediatr Oncol 37 2001 55 58
7. J.D. Buckley, T.W. Pendergrass, and C.M. Buckley Epidemiology of osteosarcoma and Ewing's sarcoma in childhood: a study of 305 cases by the Children's Cancer Group Cancer 83 1998 1440 1448
8. B. Fuchs, and D.J. Pritchard Etiology of osteosarcoma Clin Orthop Relat Res 397 2002 40 52
9. J.S. Wunder, N. Gokgoz, and R. Parkes TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study J Clin Oncol 23 2005 1483 1490
10. S. Ferrari, F. Bertoni, and L. Zanella Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma Cancer 100 2004 1936 1942
11. R. Gorlick, P. Anderson, and I. Andrulis Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary Clin Cancer Res 9 2003 5442 5453
12. M.B. Mintz, R. Sowers, and K.M. Brown An expression signature classifies chemotherapy-resistant pediatric osteosarcoma Cancer Res 65 2005 1748 1754
13. K. Ochi, Y. Daigo, and T. Katagiri Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles Int J Oncol 24 2004 647 655
14. P. Leonard, T. Sharp, and S. Henderson Gene expression array profile of human osteosarcoma Br J Cancer 89 2003 2284 2288
15. T. Nakano, M. Tani, and Y. Ishibashi Biological properties and gene expression associated with metastatic potential of human osteosarcoma Clin Exp Metastasis 20 2003 665 674
16. C. Khanna, J. Khan, and P. Nguyen Metastasis-associated differences in gene expression in a murine model of osteosarcoma Cancer Res 61 2001 3750 3759
17. C. Zucchini, M. Bianchini, and L. Valvassori Identification of candidate genes involved in the reversal of malignant phenotype of osteosarcoma cells transfected with the liver/bone/kidney alkaline phosphatase gene Bone 34 2004 672 679
18. M. Wolf, W. El-Rifai, and M. Tarkkanen Novel findings in gene expression detected in human osteosarcoma by cDNA microarray Cancer Genet Cytogenet 123 2000 128 132
19. B.H. Hoang, T. Kubo, and J.H. Healey Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma Int J Cancer 109 2004 106 111
20. G. Holzer, T. Pfandlsteiner, and M. Koschat Soluble p185(HER-2) in patients with malignant bone tumours Pediatr Blood Cancer 44 2005 163 168
21. H. Zhou, R.L. Randall, and A.R. Brothman Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification J Pediatr Hematol Oncol 25 2003 27 32
22. J.K. Anninga, M.J. van de Vijver, and A.M. Cleton-Jansen Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas Eur J Cancer 40 2004 963 970
23. C. Khanna, X. Wan, and S. Bose The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis Nat Med 10 2004 182 186
24. M.M. Retz, S.S. Sidhu, and E. Blaveri CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells Int J Cancer 114 2005 182 189
25. C. Laverdiere, B.H. Hoang, and R. Yang Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma Clin Cancer Res 11 2005 2561 2567
26. E.A. Lafleur, N.V. Koshkina, and J. Stewart Increased Fas expression reduces the metastatic potential of human osteosarcoma cells Clin Cancer Res 10 2004 8114 8119
27. H. Inaba, M. Glibetic, and S. Buck Interferon-gamma sensitizes osteosarcoma cells to Fas-induced apoptosis by up-regulating Fas receptors and caspase-8 Pediatr Blood Cancer 43 2004 729 736
28. K. Nakashima, X. Zhou, and G. Kunkel The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation Cell 108 2002 17 29
29. Y. Cao, Z. Zhou, and B. de Crombrugghe Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma Cancer Res 65 2005 1124 1128
30. D.M. Thomas, S.A. Johnson, and N.A. Sims Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma J Cell Biol 167 2004 925 934
31. M. Serra, K. Scotlandi, and G. Reverter-Branchat Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities J Clin Oncol 21 2003 536 542
32. H.R. Dhaini, D.G. Thomas, and T.J. Giordano Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma J Clin Oncol 21 2003 2481 2495
33. T. Tsunemi, S. Nagoya, and M. Kaya Postoperative progression of pulmonary metastasis in osteosarcoma Clin Orthop Relat Res 407 2003 159 166
34. M. Kaya, T. Wada, and S. Nagoya Concomitant tumour resistance in patients with osteosarcoma. A clue to a new therapeutic strategy J Bone Joint Surg Br 86 2004 143 147
35. S.S. Nathan, G.R. DiResta, and J.E. Casas-Ganem Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma Clin Cancer Res 11 2005 2389 2397